Friday, July 10, 2026
🇺🇸 FDA

Drug profile · INN

dexmedetomidine

DEXDOR

dexmedetomidine (DEXDOR) is a adrenergic receptor alpha-2 agonist.

EMA: approved NMPA: clinical trials Nervous system (N05) N05CM18
Patents linked 17
Pipeline programs 67
News articles 0
Drug details — dexmedetomidine
Class
Nervous system (N05)
Route
—
Patents
17
Programs
67
Data quality
0.83
← All drugs Related patents Pipeline programs Drug news hub Event calendar

Quick answer

dexmedetomidine (DEXDOR) is a adrenergic receptor alpha-2 agonist.

Key facts

INN dexmedetomidine
Brand DEXDOR
Mechanism Adrenergic receptor alpha-2 agonist
Therapeutic class Nervous system (N05)
ATC code N05CM18

Mechanism of action

Adrenergic receptor alpha-2 agonist

Approval history

Authority Status Date
EMA approved —
NMPA clinical trials —

Pipeline programs

Search pipeline
  1. APHP230813 Phase 3 · PARItec · Very preterm neonate (gestational age at birth < 32 WG) with
  2. DEXMEDETOMIDINE , 18F-DPA-714 Phase 3 · PARItec · Patients who survive a COVID ARDS in intensive care must be
  3. Dexmedetomidine Hcl 100 Mcg/mL Inj Phase 3 · Hospital Authority · Congenital Heart Disease in Children
  4. PEDIADEX Phase 3 · Tour Hekla · Impact on delirium of the use of DEXmedetomidine as first-l
  5. SEVOFLURANE, DEXMEDETOMIDINE HYDROCHLORIDE Phase 3 · George Institute for · Children under the age of 2 years having surgery lasting at
  6. Sublingual film containing Dexmedetomidine (BXCL501) Phase 3 · BioXcel Therapeutics · Agitation Associated With Bipolar Disorder
  7. Sublingual film containing dexmedetomidine (BXCL501) Phase 3 · BioXcel Therapeutics · Agitation
  8. Caudal Dexmedetomidine Phase 2 · Chinese Academy of · Inguinal Hernia

Related & competitor drugs

Browse all drugs
  1. aripiprazole Nervous system (N05)
  2. brexpiprazole Nervous system (N05)
  3. brivaracetam Nervous system (N03)
  4. bupivacaine Nervous system (N01)
  5. buprenorphine Nervous system (N07)
  6. caffeine citrate Nervous system (N06)

Related patents

Browse patents

  1. US 12364683

    Non-sedating dexmedetomidine treatment regimens

    Expires Mon Jul 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12138247

    Non-sedating dexmedetomidine treatment regimens

    Expires Mon Nov 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12109196

    Non-sedating dexmedetomidine treatment regimens

    Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12090140

    Non-sedating dexmedetomidine treatment regimens

    Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11998528

    Non-sedating dexmedetomidine treatment regimens

    Expires Mon May 30 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11998529

    Non-sedating dexmedetomidine treatment regimens

    Expires Mon May 30 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11931340

    Use of sublingual dexmedetomidine for the treatment of agitation

    Expires Mon Mar 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11890272

    Non-sedating dexmedetomidine treatment regimens

    Expires Mon Feb 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11839604

    Use of sublingual dexmedetomidine for the treatment of agitation

    Expires Mon Dec 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11806429

    Film formulations containing dexmedetomidine and methods of producing them

    Expires Mon Nov 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11806334

    Non-sedating dexmedetomidine treatment regimens

    Expires Mon Nov 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11786508

    Use of sublingual dexmedetomidine for the treatment of agitation

    Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11559484

    Film formulations containing dexmedetomidine and methods of producing them

    Expires Mon Jan 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 11517524

    Film formulations containing dexmedetomidine and methods of producing them

    Expires Mon Dec 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 11497711

    Film formulations containing dexmedetomidine and methods of producing them

    Expires Mon Nov 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 11478422

    Film formulations containing dexmedetomidine and methods of producing them

    Expires Mon Oct 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 10792246

    Film formulations containing dexmedetomidine and methods of producing them

    Expires Mon Oct 01 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is dexmedetomidine?

dexmedetomidine (DEXDOR) is a adrenergic receptor alpha-2 agonist.

What is the brand name for dexmedetomidine?

DEXDOR is a marketed brand name for dexmedetomidine. Check FDA Drugs@FDA for the current US label holder and prescribing information.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.